Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of Bacillus Calmette-Guerin immunotherapy for bladder cancer

Clinical Cancer Research

Volumn 12, Issue 15, 2006, Pages 4641-4644

  Kitamura, Hiroshi ^a   Torigoe, Toshihiko ^a   Honma, Ichiya ^a   Sato, Eiji ^a   Asanuma, Hiroko ^a   Hirohashi, Yoshihiko ^a   Sato, Noriyuki ^a   Tsukamoto, Taiji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD20 ANTIBODY; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PROTEIN S 100; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TUMOR CELL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; BCG VACCINE; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33748070506     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0595     Document Type: Article

References (14)

1. Bevers RFM, Kurth K-H, Schamhart DHJ. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 2004;91:607-12.
2. Kitamura H, Tsukamoto T. Early cancers: concept, diagnosis, and management. Bladder cancer. Int J Clin Oncol 2006;11:28-37.
3. O'Donnell MA. Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am 2005;32:121-31.
4. Saint F, Salomon L, Quintela R, et al. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol 2003;43:351-61.
5. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999;353:1689-94.
6. Kitamura H, Torigoe T, Honma I, et al. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy. Urology 2006;67:955-9.
7. Dalbagni G, Herr HW. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am 2000;27:137-46.
8. Hara I, Sato N, Miyake H, Muramaki M, Hikosaka S, Kamidono S. Introduction of 65 kDa antigen of Micobacterium tuberculosis to cancer cells enhances antitumor effect of BCG therapy. Microbiol Immunol 2004;48:289-95.
9. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003;170:964-9.
10. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002;12:3-13.
11. Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
12. Torigoe T, Nakazawa E, Asanuma H, et al. Establishment of a novel anti-pan HLA class I antibody revealed frequent down-regulation in primary and metastatic breast cancer tissues. J Transl Med. In press 2006.
13. Saint F, Patard JJ, Groux Muscatelli B, et al. Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment. BJU Int 2001;88:602-10.
14. Mehmut M, Takeda K, Abe M, et al. Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmette-Guérin treatment. Urol Int 2005;75:80-7.